<table id="table_12" rules="all" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 12. Virologic Response (HIV-1 RNA &lt;400 copies/mL) at Week 48 by Baseline KALETRA Susceptibility and by Number of Protease Substitutions Associated with Reduced Response to KALETRA<sup>1</sup>
</caption>
<colgroup>
<col width="4243*"></col>
<col width="4509*"></col>
<col width="4244*"></col>
<col width="25%"></col>
</colgroup>
<thead>
<tr valign="bottom">
<td>
<content stylecode="bold">Number of protease inhibitor substitutions at baseline<sup>1</sup>
</content>
</td>
<td align="center">
<content stylecode="bold">Study 888 (Single protease inhibitor-experienced<sup>2</sup>, NNRTI-naïve) n=130</content>
</td>
<td align="center">
<content stylecode="bold">Study 765 (Single protease inhibitor-experienced<sup>3</sup>, NNRTI-naïve) n=56</content>
</td>
<td align="center">
<content stylecode="bold">Study 957 (Multiple protease inhibitor-experienced<sup>4</sup>, NNRTI-naïve) n=50</content>
</td>
</tr>
</thead>
<tfoot>
<tr>
<td colspan="4">
<paragraph>1   Substitutions considered in the analysis included L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.</paragraph>
<paragraph>2   43% indinavir, 42% nelfinavir, 10% ritonavir, 15% saquinavir.</paragraph>
<paragraph>3   41% indinavir, 38% nelfinavir, 4% ritonavir, 16% saquinavir.</paragraph>
<paragraph>4   86% indinavir, 54% nelfinavir, 80% ritonavir, 70% saquinavir.</paragraph>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td>0-2</td>
<td align="center">76/103 (74%)</td>
<td align="center">34/45 (76%)</td>
<td align="center">19/20 (95%)</td>
</tr>
<tr>
<td>3-5</td>
<td align="center">13/26 (50%)</td>
<td align="center">8/11 (73%)</td>
<td align="center">18/26 (69%)</td>
</tr>
<tr>
<td>6 or more</td>
<td align="center">0/1 (0%)</td>
<td align="center">n/a</td>
<td align="center">1/4 (25%)</td>
</tr>
</tbody>
</table>